The global Cardiac Biomarkers market was valued at USD 7.96 Billion in 2020 and is expected to reach USD 17.55 Billion by year 2028, at a CAGR of 10.4%.
According to the Centre for Disease Control and Prevention (CDC), for around 610,000 people die of heart disease in United States every year, that’s 1 in every 4 deaths and more than half of the deaths due to heart disease were in men. Cardiac biomarkers are protein-based observable materials discharged into blood when the heart’s muscles are wounded which can be used as risk stratification for numerous cardiovascular diseases (CVDs) that includes Acute Myocardial Infarction (AMI), Ischemia, Congestive Heart Failure (CHF), Acute Coronary Syndrome (ACS) and others related with insufficient blood flow to heart.
The high occurrence rates of CVDs worldwide and the growing demand for POC cardiac testing kits are expected to fuel the market growth. Certain manufacturing, limited specificity and pharmacological issues and regulatory hurdles are hindering the growth of the market.
Top Companies Profiled in the Report Include:
Abbott Laboratories, Alere Inc. and Roche Diagnostics Corporation.
Market Overview:
The pharma and healthcare industry has undergone a revolutionary change owing to the COVID-19 pandemic with individuals increasing their focus on health and wellness. Companies operating in the industry have invested heavily in clinical trials and research studies to develop medications to cater to the growing unmet clinical demand on a global level. Implementation of cutting-edge technology in healthcare sector and increasing investment in research and development have contributed significantly to revenue growth of the market in the recent past. In addition, availability of favorable health insurance and reimbursement policies have also positively impacted the healthcare sector with more and more individuals opting to get treatment at hospital and clinical facilities. Rapid development of novel drugs and pharmaceuticals, increasing incidence of lifestyle and chronic diseases, establishment of state-of-the-art healthcare facilities, and rising availability of over-the-counter medications have significantly contributed to the revenue growth of the market.
Additionally, the report consists a detailed analysis of the segmentation of the Cardiac Biomarkers market based on product types and end-use/application offered in the Cardiac Biomarkers market -
Product Type (Revenue, USD Million; 2020–2028)
- Brain Natriuretic Peptide (BNPs) or NT-proBNP
- Ischemia Modified Albumin (IMA)
- Myoglobin
- Troponins (T and I)
- Myocardial muscle Creatine Kinase (CK-MB)
- Others
Location of Testing (Revenue, USD Million; 2020–2028)
- Laboratory Testing
- Point of Care Testing
Application (Revenue, USD Million; 2020–2028)
- Myocardial Infarction
- Congestive Heart Failure
- Acute Coronary Syndrome
- Atherosclerosis
- Others
End User (Revenue, USD Million; 2020–2028)
- Diagnostic Laboratories
- Hospitals and Clinics
Country-wise regional analysis covers:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East Africa
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.
Request Customization Form - https://www.reportsanddata.com/request-customization-form/1423
